Janus Henderson Group PLC Sells 14,999 Shares of DexCom, Inc. (NASDAQ:DXCM)

Janus Henderson Group PLC decreased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.6% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 559,518 shares of the medical device company’s stock after selling 14,999 shares during the period. Janus Henderson Group PLC’s holdings in DexCom were worth $77,606,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. DSM Capital Partners LLC acquired a new position in shares of DexCom in the 4th quarter valued at $28,000. Crewe Advisors LLC bought a new position in DexCom during the first quarter worth about $29,000. Valley National Advisers Inc. boosted its holdings in DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Riverview Trust Co bought a new stake in shares of DexCom in the 1st quarter valued at approximately $32,000. Finally, MV Capital Management Inc. raised its holdings in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after buying an additional 138 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Trading Up 1.0 %

Shares of DXCM stock traded up $0.72 during trading hours on Wednesday, reaching $70.42. The company had a trading volume of 3,343,980 shares, compared to its average volume of 3,466,019. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The firm has a market cap of $28.22 billion, a price-to-earnings ratio of 44.97, a P/E/G ratio of 2.04 and a beta of 1.16. The company has a 50 day moving average of $112.79 and a 200 day moving average of $122.94.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.34 EPS. On average, equities research analysts anticipate that DexCom, Inc. will post 1.7 EPS for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction on Friday, May 31st. The shares were sold at an average price of $119.24, for a total value of $77,744.48. Following the sale, the executive vice president now directly owns 67,560 shares in the company, valued at $8,055,854.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $119.24, for a total value of $77,744.48. Following the completion of the sale, the executive vice president now owns 67,560 shares in the company, valued at approximately $8,055,854.40. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the sale, the director now directly owns 25,349 shares in the company, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,483 shares of company stock valued at $401,450. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on DXCM shares. Canaccord Genuity Group reiterated a “buy” rating and issued a $145.00 price target on shares of DexCom in a research report on Tuesday, July 23rd. JPMorgan Chase & Co. cut shares of DexCom from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $145.00 to $75.00 in a research report on Friday, July 26th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. BTIG Research dropped their price objective on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a report on Friday, July 26th. Finally, Royal Bank of Canada reduced their target price on DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $111.50.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.